MBX Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MBX Nasdaq 2836 mbxbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MBX Biosciences, Inc.

Why MBX Biosciences (MBX) Is Up 12.7% After Strong Phase II Data and Equity Offering News - Nov 6th, 2025 9:35 pm
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - Nov 6th, 2025 6:00 am
DraftKings, Flutter downgraded: Wall Street's top analyst calls - Nov 4th, 2025 7:35 am
Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 228.51%: Read This Before Placing a Bet - Oct 29th, 2025 7:55 am
8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors - Oct 10th, 2025 4:20 pm
Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? - Oct 9th, 2025 7:55 am
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum - Sep 29th, 2025 6:00 am
MBX Biosciences Announces Pricing of Upsized Public Offering - Sep 24th, 2025 7:15 pm
Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet - Sep 23rd, 2025 7:55 am
MBX Biosciences (MBX) Is Up 84.0% After Positive Phase 2 Results for Canvuparatide - Has The Bull Case Changed? - Sep 23rd, 2025 5:10 am
MBX to advance hypoparathyroidism drug to Phase III trial - Sep 23rd, 2025 4:45 am
FDA clears under-the-skin Keytruda; MBX shares double on study data - Sep 23rd, 2025 2:54 am
MBX Biosciences Announces Proposed Public Offering - Sep 22nd, 2025 2:14 pm
MBX Biosciences Stock Doubles On Promising New Thyroid Disease Treatment - Sep 22nd, 2025 2:03 pm
MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study - Sep 22nd, 2025 6:28 am
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension - Sep 22nd, 2025 5:00 am
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 - Sep 19th, 2025 2:18 pm
Wall Street Set to Open Little Changed Wednesday as Investors Anticipate Fed Rate Cut - Sep 17th, 2025 7:19 am
Top 3 Biotech Stocks to Watch According to BofA Global Research - Sep 15th, 2025 10:15 am
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity - Sep 4th, 2025 6:00 am